References
- The Korean Association for the Study of the Liver and liver cirrhosis clinical research center. Clinical Practice Guideline for Liver Cirrhosis, Update. Seoul: Jin-corp, 2011; 1-83. http://www.kasl.org/bbs/index.html?code=guide&category=&gubun=&idx=&page=1&number=48&mode=view&order=&sort=&keyfield=&key
- The Korean Association for the Study of the Liver, White Paper on Liver Diseases in Korea, Seoul: The Korean Association for the Study of the Liver, 2013.
- HIRA. Healthcare Bigdata Hub. Available from http://opendata.hira.or.kr/op/opc/olap3thDsInfo.do. Accessed July 14, 2016.
- Abergel A, Rotily M, Branchoux S, et al. Chronic hepatitis C: Burden of disease and cost associated with hospitalisations in France in 2012 (The HEPC-LONE study). Clin Res Hepatol Gastroenterol 2016; 40(3): 340-8. https://doi.org/10.1016/j.clinre.2015.08.006
- Kieran JA, Norris S, O'Leary A, et al. Hepatitis C in the era of directacting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study. BMC infect Dis 2015;15:471. https://doi.org/10.1186/s12879-015-1208-1
- Stahmeyer JT, Rossol S, Bert F, et al. Cost of treating hepatitis C in Germany: a retrospective multicenter analysis. Eur J Gastroenterol Hepatol 2014;26(11):1278-85. https://doi.org/10.1097/MEG.0000000000000181
- Thongsawat S, Piratvisuth T, Pramoolsinsap C, et al. Resource Utilization and Direct Medical Costs of Chronic Hepatitis C in Thailand: A Heavy but Manageable Economic Burden. Clin Res Hepatol Gastroenterol 2014;3:12-8.
- Zhang S, Ma Q, Liang S, et al. Annual economic burden of hepatitis B virus-related diseases among hospitalized patients in twelve cities in China. J Viral Hepat 2016;23(3):202-10. https://doi.org/10.1111/jvh.12482
- Lu J, Xu A, Wang J, et al. Direct economic burden of hepatitis B virus related diseases: evidence from Shandong, China. BMC Health Serv Res 2013;13:37. https://doi.org/10.1186/1472-6963-13-37
- Lim SJ, Jo JH, Kim SH, Status of health insurance system and reform trend in major foreign countries, Seoul: National Health Insurance Service, 2014;1-126.
- Lee H, Shin E, Lee C, et al. Medical price levels of OECD countries: A Comparative Study. Research Institute for Healthcare Policy. 2012;11:1-62.
- Kwon S, Kim S, Kim T, et al. Comparison of domestic and foreign generic drug prices. National Health Insurance Service?Health Insurance Review and Assessment Service. 2010.
- Kim S. Pharmaceutical pricing policies in a global market. OECD health policy studies. 2011.
- Lee E, Kim H, Kim B et al. Comparative analysis of drug price level in Korea compared to OECD countries. Sungkyunkwan University? Korean Research-based Pharma Industry Association. 2014.
- Kim do Y, Yoon KT, Kim W, et al. Estimation of direct medical cost related to the management of chronic hepatitis C and its complications in South Korea. Medicine 2016;95(30):e3896. https://doi.org/10.1097/MD.0000000000003896
- Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370(16):1483-93. https://doi.org/10.1056/NEJMoa1316366
- Leleu H, Blachier M, Rosa I. Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C. J Viral Hepat 2015; 22(4):376-83. https://doi.org/10.1111/jvh.12311
- Linas BP, Barter DM, Morgan JR, et al. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med 2015;162(9):619-29. https://doi.org/10.7326/M14-1313
- Petta S, Cabibbo G, Enea M, et al. Cost-effectiveness of sofosbuvirbased triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2014;59(5):1692-705. https://doi.org/10.1002/hep.27010
- Pfeil AM, Reich O, Guerra IM, et al. Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in swiss patients with chronic hepatitis C. PloS one 2015;10(5):e0126984. https://doi.org/10.1371/journal.pone.0126984
- San Miguel R, Gimeno-Ballester V, Blazquez A, et al. Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. Gut 2014.
- Shepherd J, Jones J, Hartwell D, et al. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2007;11(11):1-205, iii.
- Siebert U and Sroczynski G. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security. Int J Technol Assess Health Care 2005;21(1):55-65. https://doi.org/10.1017/S0266462305050075
- Wright M, Grieve R, Roberts J, et al. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 2006;10(21):1-113, iii.
- The Korean Association for the Study of the Liver. Chronic Hepatitis Clinical Practice Guideline. 2015.
- El Khoury AC, Wallace C, Klimack WK, et al. Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas. J Med Econ 2012;15(5):887-96. https://doi.org/10.3111/13696998.2012.681332
- Kim Y, Shin S, Park J, et al. Costing methods in Healthcare. National Evidence-based Healthcare Collaborating Agency 2013.
- Shon C, Choi HY, Shim JJ, et al. The Economic Burden of Hepatitis A, B, and C in South Korea. Jpn J Infect Dis 2016;69(1): 18-27. https://doi.org/10.7883/yoken.JJID.2014.499
- Chen GF, Wei L, Chen J, et al. Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data. PloS one 2016;11(6):e0155934. https://doi.org/10.1371/journal.pone.0155934
- Chhatwal J, He T, Hur C, et al. Direct-acting antiviral agents for patients with hepatitis C virus genotype 1 infection are cost saving. Clin Gastroenterol Hepatol 2016.
- Virabhak S, Yasui K, Yamazaki K, et al. Cost-effectiveness of directacting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatmentnaive and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan. J Med Econ 2016;19(12):1144-56. https://doi.org/10.1080/13696998.2016.1206908
- Lee S, Chung W, Hyun KR. Socioeconomic costs of liver disease in Korea. Korean J Hepatol 2011;17(4):274-91. https://doi.org/10.3350/kjhep.2011.17.4.274